Interpace Biosciences Inc (NASDAQ:IDXG)

4.10
Delayed Data
As of Jan 15
 +0.07 / +1.74%
Today’s Change
2.57
Today|||52-Week Range
11.00
+30.57%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$16.2M

Company Description

Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Contact Information

Interpace Biosciences, Inc.
Morris Corporate Center 1
Parsippany New Jersey 07054
P:(855) 776-6419
Investor Relations:

Employees

Shareholders

Individual stakeholders6.39%
Mutual fund holders3.13%
Other institutional13.99%

Top Executives

Thomas W. BurnellPresident, Chief Executive Officer & Director
Fred S. KnechtelChief Financial Officer, Secretary & Treasurer
Sara A. JacksonVice President-Clinical Development
Sydney D. FinkelsteinChief Scientific Officer
Alidad MireskandariSenior Vice President-Business Development